Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Kadmon Holdings Llc
(NY:
KDMN
)
3.530
USD
UNCHANGED
Last Price
Updated: 7:25 PM EDT, Oct 23, 2020
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
3.530
Bid (Size)
3.350 (1)
Ask (Size)
3.800 (20)
Prev. Close
3.530
Today's Range
3.530 - 3.530
52wk Range
2.300 - 5.500
Shares Outstanding
78,794,746
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
Kadmon to Present at Upcoming Investor Conferences
February 24, 2021
From
ACCESSWIRE
Graviton Enters into Global Licensing Agreement for ROCK2 Inhibitor from Beijing Tide
February 23, 2021
Founder Samuel D. Waksal, Ph.D., to lead Graviton in developing therapeutics in autoimmune diseases, various cancers, certain genetic diseases, fibrotic and other disorders for which there is current...
From
PR Newswire
Performance
YTD
N/A
N/A
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
-23.59%
-23.59%
1 Year
-20.32%
-20.32%
More News
Read More
Kadmon Announces Closing of $240 Million Convertible Senior Notes Offering Including Full Exercise of $40 Million Over-Allotment Option
February 16, 2021
From
ACCESSWIRE
Kadmon Announces Pricing of $200 Million Convertible Senior Notes Offering with 100% Capped Call Transactions
February 11, 2021
From
ACCESSWIRE
Making A List Of Penny Stocks To Watch This Week? 4 To Know
February 18, 2021
Tags
Market News
From
Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
Kadmon Announces Proposed $150 Million Convertible Senior Notes Offering with Capped Call Transactions
February 10, 2021
From
ACCESSWIRE
Kadmon Announces Publication of Preclinical Data Demonstrating Anti-PD-L1/IL-15 Fusion Protein KD033 Achieves Robust Anti-Tumor Response
February 01, 2021
From
ACCESSWIRE
Kadmon Announces 12 Month Data from Pivotal Trial of Belumosudil for cGVHD at the 62nd ASH Annual Meeting
December 06, 2020
From
ACCESSWIRE
Kadmon Announces FDA Acceptance of NDA for Belumosudil in Patients With Chronic Graft-Versus-Host Disease
November 30, 2020
From
ACCESSWIRE
Kadmon to Host Virtual Key Opinion Leader Event at the 62nd ASH Annual Meeting
November 24, 2020
From
ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's After-Market Session
February 10, 2021
Tags
BZI/TFM
CGIX
ANCN
From
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.